PEARL Trial Year-One Data: Rapamycin Moved Lean Mass and Biological Age in Women
The assumption that muscle loss and chronic pain are simply what aging feels like is one of the most consequential things a person can accept too early. The year-one results of the PEARL trial, published in April 2025 in Aging, offer the most rigorous human data yet on whether rapamycin — a prescription immunosuppressant turned longevity candidate — can interrupt that trajectory. For women on 10mg once weekly, the 48-week data returned a clear signal: lean tissue mass increased by approximately 5%, and pain scores dropped substantially.
Rapamycin and the Circuit It Targets
Rapamycin was developed as an immunosuppressant for organ transplant recipients in the 1990s and remains in clinical use today. Its longevity candidacy emerged from a single biological observation: the drug inhibits mTOR (mechanistic target of rapamycin), a central cellular signaling hub that governs growth, protein synthesis, and energy metabolism.
Think of mTOR as a cell’s growth throttle. When it runs hot — which it increasingly does with age — cells prioritize expansion and protein production over internal maintenance. The housekeeping process called autophagy (a cellular recycling system that breaks down damaged proteins and organelles) gets deprioritized. mTOR inhibition shifts that balance: less growth pressure, more self-renewal.
In animal models, rapamycin consistently extends lifespan. Mice started on rapamycin in middle age lived 10–14% longer. The question PEARL asked is whether a carefully dosed, intermittent protocol could produce measurable benefits in healthy humans without the toxicity profile that comes with transplant-level dosing.
What the Numbers Show
PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) enrolled 125 adults aged 50–85, with 114 completing the 48-week protocol. Participants were randomized to placebo, 5mg rapamycin weekly, or 10mg rapamycin weekly. Women made up 35% of enrollees (n=40).
The strongest signal emerged in women assigned to 10mg (n=8). Lean tissue mass increased significantly relative to placebo at both 24 weeks (mean difference: 3.60, 95% CI 0.09–7.12, p = 0.043) and 48 weeks (mean difference: 6.19, 95% CI 0.88–11.51, p = 0.018). That translates to roughly 2.5% above baseline at 24 weeks and approximately 5% at 48 weeks. The effect size at 48 weeks (partial eta-squared = 0.202) is clinically meaningful.
Pain scores (SF-36 bodily pain scale) moved in the same direction. Women on 10mg reported 6.77 points less pain than placebo at 24 weeks (p = 0.011) and 8.07 points less at 48 weeks (p < 0.001). The SF-36 scale is structured so that lower pain scores indicate less pain — these shifts represent reported quality-of-life improvement that extended across the full study period.
The 5mg group told a different story. Emotional wellbeing scores (SF-36) improved by 5.18 points versus placebo at 48 weeks (p = 0.047), and general health self-ratings improved consistently at both 24 weeks (5.88 points, p = 0.033) and 48 weeks (5.88 points, p = 0.007, partial eta-squared = 0.166).
On safety, adverse event rates did not differ meaningfully across groups. The proportion of participants reporting any adverse event was 80.6% in the 10mg group, 77.5% in the 5mg group, and 87.2% in the placebo group. GI symptoms were modestly more common with rapamycin (10mg: 8 events; 5mg: 7; placebo: 4). Serious adverse events were rare across all groups: 3 in placebo, 2 in 5mg, 1 in 10mg.
Why Women, and Why More Clearly
The sex-stratified signal is the PEARL finding that’s attracting the most attention. Men in the trial did show some response — visceral adipose tissue (VAT) decreased at 24 weeks in both rapamycin groups relative to each other (p = 0.031) — but that effect did not hold at 48 weeks, and lean mass gains in men were not significant.
The researchers offered two plausible mechanisms. First, post-menopausal estrogen decline disrupts the hormonal environment that supports muscle protein synthesis, and may alter the regulatory relationship between estrogen signaling and mTOR. Second, women may carry higher baseline mTOR activity than men, meaning the same dose of inhibition produces a larger shift from an elevated starting point.
Both explanations are consistent with the data. Neither is confirmed. The PEARL design was not pre-specified to detect sex differences — these analyses are exploratory. That distinction matters when interpreting the strength of the finding.
Biological Age: What PEARL Measured and What It Didn’t
Media coverage of PEARL frequently cites a “4-year reduction in biological age.” That number deserves context.
PhenoAge is a validated biological age model that uses nine blood biomarkers — albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, red blood cell count, mean corpuscular volume, red cell distribution width, and alkaline phosphatase — to estimate physiological age relative to chronological age. A 60-year-old whose markers resemble a 55-year-old scores a PhenoAge of approximately 55.
The 4-year reduction figure comes from Kraig et al. (2018), a separate study of 25 older adults receiving 1mg/day rapamycin for 8 weeks, where PhenoAge was calculated retrospectively. In that cohort, the rapamycin group’s PhenoAge declined by 3.96 years on average while the placebo group’s increased by 0.15 years.
PEARL conducted its own epigenetic biomarker analysis in a subset of 24 participants (9 women, 15 men). The study’s published findings state that no statistically meaningful differences between groups were observed. PEARL’s full blood biomarker panel remained within normal reference ranges across all three groups throughout the trial.
These two findings are not contradictory — PEARL’s subset was small and may have been underpowered for this outcome. But it is inaccurate to say PEARL demonstrated a 4-year biological age reduction. The more precise statement: one small precursor study did, and PEARL’s own measurement was inconclusive.
A Prescription Drug, Not a Supplement
Rapamycin is not available over the counter. It is a Schedule I-equivalent regulated pharmaceutical in many countries, requiring a physician’s prescription. Using it for longevity is off-label everywhere — there is no approved indication for this use.
At transplant doses (2–5mg daily), rapamycin’s known risks include impaired wound healing, altered lipid profiles, thrombocytopenia, and increased infection susceptibility. PEARL’s intermittent low-dose design (once weekly) was chosen specifically to reduce these risks. Forty-eight-week safety data from PEARL is reassuring. Long-term data beyond 48 weeks does not yet exist for this dosing strategy.
In the U.S., RAPTOR (Rapamycin for Aging) and similar longevity clinics have begun prescribing off-label rapamycin to healthy adults, typically at doses comparable to PEARL’s 5–6mg weekly protocol. This remains outside established clinical guidelines and requires informed patient evaluation.
Who the Data Speaks To — and Who It Doesn’t
PEARL enrolled healthy, normative-aging adults aged 50–85. That’s the population the results apply to. The data does not extend to people with immunocompromising conditions, those on medications that significantly interact with CYP3A4 metabolism (which rapamycin relies on), people with poorly controlled blood sugar, or those preparing for or recovering from surgery.
mTOR inhibition has systemic effects. For someone with recurrent infections, autoimmune disease requiring active immune function, or healing tissue, suppressing that pathway carries different risk than it does for a metabolically healthy 60-year-old.
The PEARL trial is continuing its two-year follow-up. A larger, sex-balanced trial with pre-specified subgroup analyses would clarify whether what was seen in women at year one holds, grows, or changes. For now, the signal is real — specific, dose-consistent, and statistically robust in a population where 10mg once weekly appears to be safe. The next question is whether it replicates.
Q. Can I get rapamycin without a prescription?
No. Rapamycin (sirolimus) is a prescription-only drug. Using it for longevity purposes is off-label — not an approved indication anywhere. In the U.S., some longevity clinics do prescribe it off-label after evaluating patients individually. Purchasing it online without a prescription is illegal in most jurisdictions.
Q. Did PEARL actually show a reduction in biological age?
The PEARL trial’s own PhenoAge analysis (n=24) found no statistically significant differences between groups. The widely cited ‘4-year reduction’ comes from a separate, smaller study (Kraig 2018, n=25, 8 weeks of 1mg/day) where PhenoAge was calculated retrospectively. Those are two different datasets. PEARL’s blood biomarkers stayed within normal ranges across all groups.
Q. Why were the effects stronger in women than in men?
The research team proposed two hypotheses: post-menopausal estrogen decline may alter mTOR regulation, and women may have higher baseline mTOR activity than men. Both remain explanatory frameworks from post-hoc analysis, not confirmed mechanisms. A prospective sex-stratified study design would be needed to test either.